Valeant Short Sellers Net 343% Profit As Eyes Turn To John Paulson

HFA Padded
Mark Melin
Published on
Updated on

As Bill Ackman and Pershing Square Capital Management are licking their recent wounds due to well-publicized trades in Herbalife  Ltd. (NYSE:HLF) and Valeant Pharmaceuticals (NYSE:VRX), there are winners as well as losers. As short sellers count their profits, and gradually reduce their exposure, they eye hedge fund manager John Paulson, whose Paulson & Company is still long the stock, for a squeeze opportunity. Ackman’s loss puts him in the top five of all hedge fund gross dollar losses When the dust cleared and Ackman liquidated his 27.2 million shares of Valeant Pharmaceuticals this week at prices ranging from $11.10 to…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.